SARS MERS Spike S1

Mouse Anti SARS MERS Spike S1
Shipped with Ice Packs
In Stock

Description

SARS-CoV-1, SARS-CoV-2, and MERS-CoV Spike S1 Domains

The spike (S) protein of coronaviruses is a trimeric glycoprotein divided into two subunits:

  • S1: Mediates receptor binding via its receptor-binding domain (RBD).

  • S2: Facilitates membrane fusion through heptad-repeat (HR) regions.

FeatureSARS-CoV-2 S1MERS-CoV S1
Receptor TargetAngiotensin-converting enzyme 2 (ACE2) Dipeptidyl peptidase 4 (DPP4)
RBD SubdomainsCore + RBM (receptor-binding motif) Core + Accessory subdomain
S1/S2 Cleavage SiteContains furin cleavage motif (PRRA) Cleaved during viral biogenesis
Sequence Homology~75% with SARS-CoV-1 S1 ~22% with SARS-CoV-2 S1

Secondary Structure Variations

Infrared spectroscopy reveals distinct secondary structures among coronaviruses:

Virusα-Helix (%)β-Sheet (%)Random Coil (%)
MERS-CoV S114.420.626.4
SARS-CoV S114.926.826.4
SARS-CoV-2 S115.930.625.9

SARS-CoV-2 S1 exhibits the highest β-sheet content, potentially influencing receptor affinity and fusion dynamics .

Receptor-Binding Mechanism

  • SARS-CoV-2: ACE2 binding relies on residues K417, Y453, Y505, and N501 in the RBM .

  • MERS-CoV: DPP4 binding involves a β-propeller structure in the RBD, with critical residues in the accessory subdomain .

Cleavage-Dependent Activation

  • SARS-CoV-2: The S1/S2 junction contains a furin cleavage site (PRRA), enabling proteolytic activation at the host cell surface . This motif is absent in SARS-CoV-1 and MERS-CoV .

  • MERS-CoV: S1/S2 cleavage occurs during viral assembly or host cell encounter, facilitating fusion .

Immunogenic and Therapeutic Targets

Target RegionSARS-CoV-2 S1MERS-CoV S1
N-Terminal Domain (NTD)Neutralizing antibodies target NTD Accessory proteins (e.g., 3, 4a)
RBDmAbs (e.g., REGN-COV2) block ACE2 binding mAbs target DPP4-binding site
S1/S2 JunctionInhibitors block furin cleavage Peptides disrupt S-N interaction

Host Specificity and Transmission

  • SARS-CoV-2: Ubiquitous furin expression enables broad tissue tropism .

  • MERS-CoV: DPP4 expression in respiratory epithelia limits host range .

Vaccine Development

  • SARS-CoV-2: mRNA vaccines (e.g., Pfizer-BioNTech) target the full-length S protein, including S1 .

  • MERS-CoV: Recombinant S1 subunits induce neutralizing antibodies in preclinical models .

Post-Translational Modifications

SARS-CoV-2 S1/S2 junction phosphorylation (e.g., at Ser680 and Ser686) may regulate furin cleavage efficiency .

Broad-Spectrum Antivirals

  • Peptide Inhibitors: HR1/HR2-derived peptides block fusion (e.g., MERS-CoV Spike CD peptides) .

  • Monoclonal Antibodies: Cross-reactive antibodies targeting conserved S2 regions (e.g., HR1) are under investigation .

Product Specs

Introduction
The SARS coronavirus is characterized by its envelope, which contains three key structural proteins: membrane (M), envelope (E), and spike (S) proteins. The spike (S) glycoprotein plays a crucial role in the virus's ability to infect cells. It interacts with a cellular receptor, facilitating membrane fusion and enabling the virus to enter the target cell. Due to its critical role in the infection cycle, the S-protein is a primary target for neutralizing antibodies. Research has identified SARS as a human coronavirus. Human coronaviruses are a significant cause of upper respiratory tract infections, including the common cold. These viruses are known for having positive-stranded RNA genomes, which are the largest among known RNA viruses (27-31 kb). The initial step in coronavirus infection involves the binding of the viral spike protein, a 139-kDa protein, to specific receptors on the host cell's surface. The spike protein serves as the primary surface antigen for the coronavirus. When analyzing culture supernatants from SARS virus-infected cells, a 46 kDa nucleocapsid protein is prominently observed. This suggests that the nucleocapsid protein is a significant immunogen, potentially valuable for early diagnostic purposes.
Description
The SARS MERS Spike-S1 antibody specifically targets the S1 domain of the spike protein found in the MERS virus.
Formulation
The antibody is provided at a concentration of 1 mg/ml in a solution of PBS containing 0.1% NaN3.
Physical Appearance
The product is a sterile filtered liquid.
Purity
The purity of the antibody is greater than 90% as determined by SDS-PAGE gel analysis.
Applications
This antibody is suitable for use in ELISA applications.
Stability
For short-term storage, the antibody should be kept at 4°C, where it is stable for up to 2 weeks. For long-term storage, it is recommended to store the antibody at -20°C.
Purification Method

Protein A affinity purified.

Type
Mouse antibody Monoclonal.
Isotype

IgG1.

Q&A

Basic Research Questions

  • What are the key structural differences between MERS-CoV, SARS-CoV, and SARS-CoV-2 S1 proteins?

The S1 subunits of these coronaviruses exhibit distinct secondary structural characteristics despite some sequence similarities. Infrared spectroscopic studies reveal that SARS-CoV-2 S1 contains a significantly higher proportion of β-sheet structures compared to MERS-CoV and SARS-CoV. At serological pH (7.4), the percentage of β-sheet content increases progressively from MERS-CoV (20.6%) to SARS-CoV (26.8%) and SARS-CoV-2 (30.6%) . Notably, SARS-CoV-2 S1 uniquely displays an extended β-sheet absorption band at 1619 cm⁻¹, which is absent in the other coronaviruses .

Secondary StructureMERS-CoVSARS-CoVSARS-CoV-2
α-helixNot specified14.9%15.9%
β-sheet20.6%26.8%30.6%
Random coilNot specified26.4%25.9%

This structural variation may explain differences in receptor binding affinity and viral infectivity among these coronaviruses.

  • How does sequence similarity compare with structural similarity among coronavirus S1 domains?

A seemingly paradoxical relationship exists between sequence similarity and structural differences among coronavirus S1 proteins. SARS-CoV and SARS-CoV-2 S1 domains share approximately 78% sequence similarity, yet infrared spectroscopy reveals substantial differences in their secondary structures . In contrast, MERS-CoV S1 has much lower sequence similarity with either SARS-CoV S1 (36.4%) or SARS-CoV-2 S1 (33.3%) .

  • What experimental methods are most effective for studying S1 protein structure?

Multiple complementary techniques are employed to elucidate the structure of coronavirus S1 proteins:

  • Infrared (IR) Spectroscopy: Used to determine secondary structure composition by analyzing the amide I vibrational band (1600-1700 cm⁻¹). This technique can quantify the relative proportions of α-helices, β-sheets, and random coils . Researchers typically perform spectral component analysis by fitting component bands to the experimental spectrum, with each component corresponding to a specific secondary structure element.

  • Cryo-Electron Microscopy (Cryo-EM): Enables visualization of the three-dimensional structure of S proteins at near-atomic resolution without requiring protein crystallization . This technique has been instrumental in resolving the prefusion conformations of coronavirus spike proteins.

  • Affinity Purification-Mass Spectrometry (AP-MS): While not directly a structural technique, this approach helps identify protein-protein interactions of the S1 domain, providing insights into its functional structure in different cellular contexts .

For optimal results, researchers should integrate data from multiple techniques, as each provides complementary information about different structural aspects of the S1 domain.

  • What is the relationship between coronavirus mortality rates and S1 protein characteristics?

The mortality rates of SARS and MERS infections show significant differences that may partially reflect S1 protein characteristics:

MERS-CoV appears significantly more lethal than SARS-CoV, with a mortality rate exceeding 30% (45 deaths among 82 diagnosed cases in early data) . While multiple factors contribute to this difference, S1 structural variations may play a role. MERS-CoV S1 has a distinct secondary structure profile compared to SARS-CoV and SARS-CoV-2, with different β-sheet content .

The relationship between mortality and S1 characteristics requires investigation at multiple levels:

  • Structural analysis of receptor binding domains

  • Quantification of receptor binding affinities

  • Assessment of conformational stability under different conditions

  • Analysis of tissue tropism based on S1 interactome studies

These approaches help elucidate how S1 variations contribute to the different clinical presentations and mortality rates of coronavirus infections.

Advanced Research Questions

  • How does pH affect the secondary structure of coronavirus S1 proteins?

The SARS-CoV-2 S1 glycoprotein exhibits remarkable conformational plasticity in response to pH changes, which may contribute to its infectivity across diverse tissue environments. Research demonstrates that this protein can "rapidly adapt its secondary structure to different pH environments" .

When transitioning from serological pH (7.4) to mildly acidic or alkaline conditions, SARS-CoV-2 S1 undergoes substantial conformational changes . This adaptability could be crucial for maintaining functionality during:

  • Initial attachment at the cell surface (neutral pH)

  • Endocytosis (progressively acidifying environment)

  • Fusion events (typically requiring specific conformational triggers)

To investigate these pH-dependent effects, researchers employ buffer-controlled infrared spectroscopy to measure the amide I absorption band under different pH conditions, followed by spectral component analysis to quantify changes in secondary structure elements . This adaptability to different pH environments may represent an evolutionary advantage for SARS-CoV-2, potentially contributing to its broader tissue tropism compared to earlier coronaviruses.

  • What are the differences in S1 protein interactomes across different human cell types?

The S1 domain interacts with diverse host proteins beyond primary receptors, with significant variations across different cell types. Affinity purification-mass spectrometry (AP-MS) studies reveal:

  • In human kidney cells (HK-2): 55 specific S1 interactors identified

  • In normal colon cells (NCM460D): 80 interactors found

  • In colorectal adenocarcinoma cells (Caco-2): 85 interactors detected

These interactomes show cell-type specificity in terms of both protein composition and subcellular localization:

  • Exosomal components were enriched across all three cell types, suggesting S1 may influence exosome-mediated signaling or viral spread .

  • Mitochondrial components showed cell-type-specific patterns, with mitochondrial matrix proteins more enriched in NCM460D cells, while mitochondrial inner membrane proteins were more prominent in HK-2 cells .

The large number of interactors suggests that S1 may influence multiple cellular processes beyond receptor binding, potentially explaining the diverse pathological manifestations of coronavirus infections. This challenges the view that S1 merely functions in receptor recognition.

  • How do researchers differentiate between specific S1 protein interactions and contaminants in pulldown experiments?

Distinguishing genuine protein interactions from background contaminants in affinity purification experiments requires robust experimental design and computational filtering. The methodological approach includes:

  • Experimental Controls:

    • Pre-incubation of membrane protein extracts with solid supports alone serves as a negative control

    • Parallel processing of samples and controls under identical conditions

  • Computational Filtering Pipeline:

    • Application of the SAINT (Significance Analysis of INTeractome) algorithm to compare sample and control datasets

    • Retention of only proteins never occurring in any control samples

    • Further filtering using the Contaminant Repository for Affinity Purification (CRAPome) 2.0 database

    • Elimination of proteins reported as contaminants in >50% of similar experiments

This stringent filtering process typically reduces the initial list of identified proteins substantially, resulting in higher confidence interactome datasets. For the S1 interactomes, this approach yielded 55, 80, and 85 high-confidence interactors in HK-2, NCM460D, and Caco-2 cells, respectively .

  • What protease inhibitors are effective against MERS-CoV and SARS-CoV-2, and how is their efficacy determined?

Protease inhibitors represent an important class of antiviral compounds targeting coronavirus main proteases (Mpro). While not directly targeting S1 proteins, they provide insights into coronavirus inhibition strategies:

Nirmatrelvir (formerly PF-07321332) has demonstrated inhibitory activity against several coronavirus proteases, including those of SARS-CoV-2 and MERS-CoV . In contrast, ensitrelvir shows a narrower spectrum of activity .

Research methodology for evaluating protease inhibitors includes:

  • Established protease assays to quantify inhibition across different coronavirus proteases

  • Surrogate virus-based systems to simulate clinical use and resistance development

  • Selection experiments to identify resistance mutations (e.g., T21I, M49L, S144A, E166A/K/V, L167F for SARS-CoV-2 Mpro)

  • Structural modeling to understand the steric effects of catalytic site mutations (e.g., S142G, S142R, S147Y, A171S for MERS-CoV Mpro)

These approaches provide crucial data for developing effective coronavirus therapeutics with high barriers to resistance.

  • What cellular components are significantly enriched in S1 interactomes?

Functional enrichment analysis of S1 interactomes reveals several overrepresented cellular components, suggesting specific roles for S1 beyond primary receptor binding:

  • Exosomal Components: Significantly enriched across all three cell types (HK-2, NCM460D, and Caco-2), with fold enrichments of 5-7 depending on the cell line . This suggests S1 may influence exosome-mediated signaling or viral spread, potentially manipulating host exosomal vesicles to deliver pro-inflammatory molecules.

  • Mitochondrial Components: Enriched with fold enrichments of approximately 7 in both HK-2 and NCM460D cells, but with cell-type specific patterns:

    • "Mitochondrial matrix" more enriched in NCM460D cells

    • "Mitochondrial inner membrane" more prominent in HK-2 cells

To identify these enriched components, researchers perform over-representation analysis using tools like FunRich 3.1.3, querying Gene Ontology databases for subcellular localization terms and applying statistical filters (typically p-value < 0.01 with Benjamini-Hochberg correction) . Components with fold enrichment > 3 are considered significantly overrepresented.

The enrichment of mitochondrial components is particularly intriguing, as it suggests potential viral interference with energy metabolism or mitochondrial-associated immune signaling pathways.

  • How can interdisciplinary research approaches enhance our understanding of coronavirus S1 proteins?

Interdisciplinary research frameworks are essential for comprehensive understanding of coronavirus S1 proteins and developing effective countermeasures. The Centre for Emerging Infectious Diseases (CEID) has established a platform for such interdisciplinary research on SARS-CoV and MERS-CoV, focusing on prevention and control applications .

Effective interdisciplinary approaches should integrate:

  • Structural Biology: Determining S1 conformations through techniques like IR spectroscopy and cryo-EM

  • Molecular Biology: Analyzing sequence-structure relationships and key mutations

  • Cell Biology: Mapping interactomes across different cell types

  • Biochemistry: Characterizing pH-dependent conformational changes

  • Epidemiology: Correlating molecular properties with disease characteristics

  • Computational Biology: Modeling protein structures and predicting binding interactions

This integrated approach can address complex questions that single disciplines cannot answer alone. For example, combining structural analysis of S1 proteins with interactome studies can reveal how specific structural features enable interactions with different host proteins across various tissue types.

Product Science Overview

Introduction

The Mouse Anti SARS MERS Spike S1 antibody is a monoclonal antibody specifically designed to target the S1 subunit of the spike proteins found in SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus) and MERS-CoV (Middle East Respiratory Syndrome Coronavirus). These spike proteins play a crucial role in the virus’s ability to infect host cells, making them a key target for therapeutic and diagnostic applications.

Spike Protein Structure

The spike protein of coronaviruses is a large type I transmembrane protein that is essential for viral entry into host cells. It consists of two subunits:

  • S1 Subunit: Contains the receptor-binding domain (RBD) responsible for recognizing and binding to the host cell receptor.
  • S2 Subunit: Facilitates the fusion of the viral and host cell membranes, allowing the viral genome to enter the host cell.
Importance of S1 Subunit

The S1 subunit is particularly important because it contains the RBD, which is the primary target for neutralizing antibodies. By binding to the RBD, these antibodies can block the virus from attaching to and entering host cells, thereby preventing infection.

Development of Mouse Anti SARS MERS Spike S1 Antibody

The development of the Mouse Anti SARS MERS Spike S1 antibody involves several key steps:

  1. Immunization: Mice are immunized with a recombinant form of the spike S1 protein to elicit an immune response.
  2. Hybridoma Technology: B cells from the immunized mice are fused with myeloma cells to create hybridomas, which are screened for the production of antibodies that specifically bind to the S1 subunit.
  3. Purification: The selected monoclonal antibodies are purified from the hybridoma culture supernatant using protein A or G affinity chromatography.
Applications

The Mouse Anti SARS MERS Spike S1 antibody has several important applications:

  • Diagnostic Testing: Used in ELISA and Western blot assays to detect the presence of SARS-CoV and MERS-CoV in clinical samples.
  • Research: Helps in studying the mechanisms of viral entry and the development of antiviral therapies.
  • Therapeutics: Potential use in passive immunization strategies to provide immediate protection against SARS-CoV and MERS-CoV infections.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.